CD4 News and Research

RSS

Specific immune signature identified in COVID-19 patients

Researchers at King’s College London and collaborators have identified an “immune signature” that could help researchers better understand coronavirus disease 2019 (COVID-19) and serve as a valuable resource for predicting patient prognosis and informing clinical risk-based stratification.

10 Jun 2020

New strategy may facilitate development of multi-epitope peptide vaccine against SARS-CoV-2

By combining T and B lymphocyte analysis with manufacturability heuristic, researchers from the US and Germany proposed a set of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine peptides to use in subsequent animal studies and clinical trials. Their paper is currently available on the bioRxiv preprint server.

7 Jun 2020

Specific immune suppression leads to severe COVID-19 disease

A new study published online on the preprint server medRxiv in May 2020 reports that specific changes in the way the human immune system responds to COVID-19 determine whether the individual develops moderate or severe illness.

2 Jun 2020

Ludwig Cancer Research study profiles immune landscape of brain tumors

A Ludwig Cancer Research study has profiled, in a sweeping comparative analysis, the distinct immune landscapes of tumors that arise in the brain, or gliomas, and those that metastasize to the organ from the lungs, breast and skin.

28 May 2020

Many different T cell receptors recognize SARS-CoV-2 antigenic sites

The global COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is spreading over the world. However, not much is known about how the adaptive immune response kicks in following the viral challenge. This knowledge is crucial to predicting the efficacy of a vaccine and estimating the chances of reinfection.

26 May 2020

Do parasites protect against SARS-CoV-2?

The world has rarely seen such a readily transmissible infection as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) over the last century. Within five months, the virus has created a Tsunami of COVID-19 positive cases, comprising almost 4.88 million people and causing 322,000 deaths.

19 May 2020

First cellular immunology data to help guide social distancing recommendations

Scientists around the world are racing to develop a vaccine to protect against COVID-19 infection, and epidemiologists are trying to predict how the coronavirus pandemic will unfold until such a vaccine is available.

15 May 2020

A 'window of vulnerability' for re-infection with HIV after stem cell transplantation

Some people with HIV need to undergo an allogeneic stem cell transplantation in order to treat different types of blood cancer. Most of the patient's immune cells are eliminated during these transplantations.

14 May 2020

Does HIV infection increase the severity of COVID-19?

A new study by researchers at the New York University Grossman School of Medicine and published on the preprint server medRxiv* in May 2020 reports that being infected with HIV at the time of acquiring COVID-19 does not significantly increase the severity of illness or the risk of complications.

13 May 2020

Could JAK blockers help treat COVID-19?

A new study published in the journal Science Immunology in May 2020 reports that compounds that safely inhibit the JAK protein could be useful in treating COVID-19.

12 May 2020

Study demonstrates dynamic and broad-scale immune alterations in COVID-19 patient

A new case report released on the preprint server medRxiv* provides a detailed longitudinal analysis of the immune response associated with a fatal case of coronavirus disease (COVID-19). It highlights the need for addressing the source of hyper inflammation in the treatment approach.

10 May 2020

Low CD8 and NK cell counts in the lung linked to high SARS-CoV-2 ACE2 receptor levels

A new study published on the preprint server bioRxiv in April 2020 reports that low levels of specific immune cells, namely, CD8 T cells and NK cells, are linked to higher expression of the ACE2 molecule, which acts as a receptor for the CoV.

6 May 2020

Hydroxychloroquine shown to slow recovery for COVID-19 patients

As researchers try to piece together a therapeutic strategy against the ongoing COVID-19 pandemic, a recent retrospective study from Cleveland Clinic Abu Dhabi, assessed the Hydroxychloroquine's efficacy in increasing SARS-CoV-2 viral clearance, finding that it appeared to significantly slow viral clearance in mild to moderately ill COVID-19 patients.

5 May 2020

Uncovering immune cell reactions in COVID-19

A new study published on the preprint server medRxiv in April 2020 suggests that an overactive immune response is responsible for the more severe manifestations of the illness.

4 May 2020

EPFL scientists identify new therapeutic target for Non-Hodgkin lymphoma

Non-Hodgkin lymphoma is a group of cancers that originate in the lymph nodes and affect white blood cells of the immune system called B cells.

23 Apr 2020

Immunity to coronavirus infection may help stem the pandemic

The raging coronavirus pandemic is causing immense fear and uncertainty across the world. One of the most distressing aspects of COVID-19 disease is the seemingly large number of unknowns. These include the burning question of immunity. Does a person who was sick with the COVID-19 and then recovered or was infected without symptoms, have immunity against re-infection?

21 Apr 2020

Gimsilumab trial starts in first US patient with ARDS and COVID-19

The first American patient with COVID-19 and acute respiratory distress syndrome (ARDS) has been put on the drug gimsilumab at Temple University Hospital, as part of the BREATHE clinical trial. The trial, sponsored by Roivant Sciences, will evaluate the effectiveness of intravenous gimsilumab in preventing death in patients with COVID-19 and ARDS.

16 Apr 2020